A new ex vivo model treated animal wounds with mesenchymal stromal cells (MSCs) and reduced MRSA infection, expanding therapeutic options for humans.
List view / Grid view
Scientists have discovered drug targets in the neural circuits that encode memories, paving the way for the treatment of brain disorders.
Learn how you can partner for success with Eurofins Beacon Discovery’s industry leading GPCR experts to support your program from concept to clinic.
Researchers discovered that glioblastoma cells rely on biotin distribution for growth, leading to possible future drug combinations.
A novel gene therapy has fully corrected whole-body alterations in a rat model, paving the way for Morquio A therapies.
Researchers have identified a spider-like antibacterial mechanism by immune cells that could inspire Staphylococcus aureus treatments.
The new features in Clampex 11 software enhance functionality in Protocol Editor, increasing the user's ability to create complex experimental protocols involving many command stimulations.
An NIH team have built a cellular map of chronic multiple sclerosis (MS) lesions to identify cells that drive inflammation and potential therapies.
Researchers have developed a new method that can rapidly count the number of T cells in a tumour, helping to predict patient response to therapies.
The Gut Cell Atlas comprises 428,000 cells in the gut and sheds light on the origin of Crohn’s disease and other intestinal diseases.
An imaging technique identified emerging drugs that activate the STING protein to alter metabolic pathway activity in cancer cells.
Sphingosine-1 phosphate was found to regulate blood glow in cerebral blood vessels in mice, presenting a potential therapeutic target.
The new study modelled the process of capsid disassembly of the hepatitis B virus at an atomic level to help develop targeted therapies.